Clinical Trial of SAHA in Patients With Breast Cancer
Recruitment status was Active, not recruiting
- evaluate the safety of Vorinostat.
- evaluate the effectiveness of Vorinostat in treating breast cancer
- evaluate how the study subject's body reacts to Vorinostat, how these reactions relate to the subject's genes, and whether protein changes in the subject blood may be used to predict how the subject's cancer will respond to Vorinostat
We hypothesize that Vorinostat, as a novel class of anti-cancer agents, may induce response in patients with recurrent or metastatic breast cancer who have been previously treated with anthracyclines and taxanes. In addition, we hypothesize that serum Vorinostat levels may correlate with clinical response and toxicities, and that Vorinostat may induce unique protein changes in the plasma in responding patients, and that these proteins may in turn be used as predictive biomarkers for treatment response.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase I/II Clinical Trial of Vorinostat in Patients With Recurrent and/or Metastatic Breast Cancer|
- Clinical laboratory tests [ Time Frame: Screening (Visit 1) and weekly during Cycle 1 ] [ Designated as safety issue: Yes ]Laboratory tests will include the following: full blood count, albumin, alkaline phosphatase, total bilirubin, BUN, calcium, chloride, creatinine, glucose, LDH, potassium, total protein, AST, ALT, sodium and uric acid
- Vital signs [ Time Frame: Screening (Visit 1) and at subsequent visits ] [ Designated as safety issue: Yes ]Vital signs will include pulse, blood pressure, temperature, and respiration rate. Any treatment-emergent clinically significant vital sign abnormalities should be reported and followed as an adverse event.
- Electrocardiograms [ Time Frame: (Visit 1) and every 12 weekly while on treatment. ] [ Designated as safety issue: Yes ]ECG results will be reviewed by the investigator, and any treatment-emergent clinically significant ECG abnormality should be reported and followed as an adverse event.
- Vorinostat concentration in serum samples [ Time Frame: Cycle 1 Day 1 (Week 1) and Cycle 1 Day 15 (Week 3) ] [ Designated as safety issue: No ]Vorinostat and its two metabolites SAHA-glucuronide and n-phenyl succinamic acid in human serum samples will be isolated by high throughput liquid chromatograph (HTLC) on-line extraction system.AUC, terminal elimination rate constant,total serum clearance (CL), volume of distribution (Vz) and bioavailability after oral administration will be calculated
- Level of histone H3 acetylation [ Time Frame: Baseline and 3 weeks after initiation of Vorinostat treatment ] [ Designated as safety issue: No ]10ml whole blood will be collected in heparinized tubes at baseline and 3 weeks after initiation of Vorinostat treatment, and centrifuged to obtain peripheral mononuclear cells. Histones will be isolated and acetylated histone H3 evaluated by Western blot analysis and enzyme linked immunosorbent assay (ELISA).
- Known functional single nucleotide polymorphisms [ Time Frame: prior to start of treatment ] [ Designated as safety issue: No ]Known functional single nucleotide polymorphisms (SNPs) of genes encoding for proteins that are relevant to the pharmacokinetic disposition and pharmacodynamics of Vorinostat will be characterized. More comprehensive genotyping using high-throughput sequencing techniques will be carried out in 'outliers' who have extreme pharmacokinetic parameters, or who experience exceptional toxicity or tumor response, to identify novel functional SNPs.
- Baseline plasma protein profiles and changes in response to chemotherapy [ Time Frame: baseline, on day 1 of each subsequent treatment cycle for the first 6 cycles, followed by 3 monthly until documented disease progression. ] [ Designated as safety issue: No ]Plasma proteomics studies using SELDI-MS with the Ciphergen technology will be collected serially to identify protein markers that are associated with Vorinostat response.
- Tumor histone acetylation studies, genomics and proteomics studies (optional) [ Time Frame: at baseline, and 3 weeks after initiation of Vorinostat treatment ] [ Designated as safety issue: No ]Tumor samples will be snap frozen in liquid nitrogen for subsequent RNA and protein extraction for tumor histone acetylation studies, gene expression studies and proteomic studies in an attempt to identify biomarkers that correlate with Vorinostat biological effects and clinical response.
|Study Start Date:||January 2007|
|Estimated Study Completion Date:||January 2015|
|Estimated Primary Completion Date:||January 2015 (Final data collection date for primary outcome measure)|
A phase I portion that will determine the safety of 400mg Vorinostat once a day, continuously in the Asian population. A pre-determined dose reduction schema will be followed in the event of significant dose-limiting toxicities at this dose. Phase II will recruit additional patients at the determined dose with the goal of evaluating drug efficacy.
MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
Other Name: MK-0683
Please refer to this study by its ClinicalTrials.gov identifier: NCT00416130
|National University Hospital|
|Singapore, Singapore, 149547|
|National Cancer Centre|
|Singapore, Singapore, 169610|
|Study Chair:||Soo Chin LEE, MBBS,MRCP||National University Hospital, Singapore|